Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
$0.00
-50.0%
$0.00
$0.00
$0.00
N/A-1.356.91 million shs10,030 shs
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$25.08
$9.20
$4.30
$13.66
$1.26B1.531.18 million shs2 shs
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
$0.00
$0.00
$1.59
$1K1.535.25 million shsN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
$8.13
+1.4%
$7.77
$5.67
$30.60
$133.11M-0.09165,333 shs19,412 shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$4.99
+2.1%
$4.45
$3.81
$6.37
$292.90M0.68604,817 shs293,730 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
0.00%-50.00%-50.00%-50.00%-88.89%
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
0.00%+175.00%+175.00%+175.00%+175.00%
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
0.00%0.00%0.00%0.00%-99.99%
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
0.00%-3.62%-0.43%-4.19%-62.66%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
0.00%+4.48%+13.76%+20.63%-6.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/AN/AN/AN/AN/AN/AN/AN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
4.2498 of 5 stars
3.23.00.04.21.91.71.3
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
4.4049 of 5 stars
3.82.00.04.20.63.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
0.00
N/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
0.00
N/AN/AN/A
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
0.00
N/AN/AN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
2.33
Hold$24.00195.38% Upside
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
3.50
Strong Buy$16.50230.40% Upside

Current Analyst Ratings Breakdown

Latest RAPT, VNDA, ENDV, MTEM, and FLXN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $8.00
5/22/2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$48.00
5/14/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$13.00
5/13/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/7/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
$10K12.07N/AN/A($0.08) per share0.00
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$85.55M14.75N/AN/A($0.34) per share-73.76
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
$23.48M0.00N/AN/A$0.78 per share0.00
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
$1.53M87.83N/AN/A$11.51 per share0.71
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$198.77M1.48N/AN/A$9.24 per share0.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
-$2.80MN/A0.00N/AN/AN/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/A
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
-$8.12M-$2.70N/AN/AN/A-61.35%-260.50%-46.90%N/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
-$129.87M-$19.20N/AN/AN/AN/A-81.47%-70.24%8/6/2025 (Estimated)
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$18.90M-$0.75N/AN/AN/A-21.98%-8.30%-6.85%7/30/2025 (Estimated)

Latest RAPT, VNDA, ENDV, MTEM, and FLXN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.34N/AN/AN/A$54.77 millionN/A
5/8/2025Q1 2025
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
-$2.48-$0.64+$1.84-$0.08N/AN/A
5/7/2025Q1 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
N/AN/AN/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/AN/A
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/AN/AN/AN/AN/A
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
N/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/A
4.38
4.05
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
N/A
1.56
1.56
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
N/A
21.11
21.11
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/A
3.93
3.91
CompanyEmployeesShares OutstandingFree FloatOptionable
Endonovo Therapeutics, Inc. stock logo
ENDV
Endonovo Therapeutics
11.21 billion1.14 billionNot Optionable
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
25750.32 million45.73 millionNo Data
Molecular Templates, Inc. stock logo
MTEM
Molecular Templates
2606.58 million5.67 millionNo Data
Rapt Therapeutics stock logo
RAPT
Rapt Therapeutics
8016.54 million16.15 millionOptionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
29058.93 million53.04 millionOptionable

Recent News About These Companies

VNDA - Vanda Pharmaceuticals Inc Chart - Morningstar
Brokers Issue Forecasts for VNDA FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Endonovo Therapeutics stock logo

Endonovo Therapeutics OTCMKTS:ENDV

$0.0001 0.00 (-50.00%)
As of 07/3/2025 11:17 AM Eastern

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

Flexion Therapeutics stock logo

Flexion Therapeutics NASDAQ:FLXN

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Molecular Templates stock logo

Molecular Templates NASDAQ:MTEM

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Rapt Therapeutics stock logo

Rapt Therapeutics NASDAQ:RAPT

$8.12 +0.12 (+1.44%)
Closing price 07/3/2025 01:04 PM Eastern
Extended Trading
$7.54 -0.59 (-7.26%)
As of 07/3/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$4.99 +0.10 (+2.13%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.